The Evolution of a Glycoconjugate Vaccine for Candida albicans

摘要: The monoclonal antibody C3.1 has been found to afford protection against Candida albicans, an opportunistic fungal pathogen. exceptional inhibition profile of propelled synthetic and immunochemical studies antibody–oligosaccharide interactions, leading the development candidate vaccines. β1,2-linked mannan fungal-cell-wall phosphomannan complex is a protective antigen that exhibits well-defined conformation. A trisaccharide conjugated tetanus toxoid generates antibodies in rabbits, STD-NMR show these approximate binding antibody. This simple trisaccharide–tetanus conjugate was strong immunogen but it poorly immunogenic mice. However, when carbohydrate targeted at dendritic cells incorporated this vaccine, improved uptake processing resulted five-fold higher mannan-specific response together with cytokine appropriate for antifungal vaccine. When same T-cell peptide derived from cell-wall protein, resulting glycopeptide–tetanus engendered peptide- carbohydrate-specific afforded live challenge by C. albicans without requiring adjuvant.